BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live2025-03-31

BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.

The company said the recommendation is based on a phase 3 study that showed a median overall survival of 15.5 months in patients treated with Tevimbra plus chemotherapy compared with 13.5 months for placebo plus chemotherapy.

BeiGene said Tevimbra with chemotherapy was also generally well tolerated, with no new safety signals observed.

Shares of the company were up more than 3% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523486309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523486309","market":"us","top_or_hot":-1,"title":"BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.</p><p>The company said the recommendation is based on a phase 3 study that showed a median overall survival of 15.5 months in patients treated with Tevimbra plus chemotherapy compared with 13.5 months for placebo plus chemotherapy.</p><p>BeiGene said Tevimbra with chemotherapy was also generally well tolerated, with no new safety signals observed.</p><p>Shares of the company were up more than 3% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.</p><p>The company said the recommendation is based on a phase 3 study that showed a median overall survival of 15.5 months in patients treated with Tevimbra plus chemotherapy compared with 13.5 months for placebo plus chemotherapy.</p><p>BeiGene said Tevimbra with chemotherapy was also generally well tolerated, with no new safety signals observed.</p><p>Shares of the company were up more than 3% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523486309","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523486309","pubTimestamp":1743420770,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a fi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1500":"做空集合股","BK1161":"生物科技","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","ONC":"百济神州","BK4139":"生物科技","06160":"百济神州","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD"},"translate_title":"百济神州表示EMA小组建议批准Tevimbra治疗肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"ONC":0.9},"content_text":"BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.The company said the recommendation is based on a phase 3 study that showed a median overall survival of 15.5 months in patients treated with Tevimbra plus chemotherapy compared with 13.5 months for placebo plus chemotherapy.BeiGene said Tevimbra with chemotherapy was also generally well tolerated, with no new safety signals observed.Shares of the company were up more than 3% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523486309","isCrawlerRequest":true}